Quit smoking medication
Pro Research Analysisby 
Searched over 200M research papers
Quit Smoking Medication: An Overview of Pharmacological Interventions
Introduction to Smoking Cessation Medications
Smoking is a leading cause of preventable illness and premature death worldwide. Various medications have been developed to aid individuals in quitting smoking, with nicotine replacement therapy (NRT), bupropion, and varenicline being the most commonly used and licensed in Europe and the USA. Other treatments, such as cytisine and nortriptyline, have also shown promise in aiding smoking cessation .
Nicotine Replacement Therapy (NRT)
Efficacy of NRT
NRT works by providing a controlled dose of nicotine to reduce withdrawal symptoms and cravings. Studies have shown that NRT is effective in increasing the odds of quitting smoking compared to placebo, with an odds ratio (OR) of 1.84 . Different forms of NRT, including patches, gum, inhalers, and lozenges, have been found to be similarly effective, although combination NRT (using more than one form) tends to be more effective than single forms .
Safety of NRT
NRT is generally considered safe, with no significant increase in serious adverse events (SAEs) compared to placebo . This makes it a viable option for many individuals seeking to quit smoking.
Bupropion
Efficacy of Bupropion
Bupropion, an antidepressant, has been shown to be effective in aiding smoking cessation. It works by alleviating withdrawal symptoms and reducing the urge to smoke. High-certainty evidence indicates that bupropion increases smoking cessation rates compared to placebo, with a risk ratio (RR) of 1.60 Hajizadeh2023Howes2020. However, it is less effective than varenicline and combination NRT Hajizadeh2023Howes2020.
Safety of Bupropion
While bupropion is effective, it is associated with an increased risk of adverse events, including psychiatric symptoms and seizures. The risk of serious adverse events is higher compared to placebo, but the evidence is imprecise Hajizadeh2023Howes2020. Therefore, monitoring and caution are advised when using bupropion.
Varenicline
Efficacy of Varenicline
Varenicline, a nicotine receptor partial agonist, is highly effective in helping people quit smoking. It works by reducing withdrawal symptoms and the satisfaction derived from smoking. Varenicline has been shown to be more effective than both placebo (RR 2.32) and bupropion (RR 1.36) Cahill2013Livingstone-Banks2023. It is also more effective than single forms of NRT but comparable to combination NRT Cahill2013Livingstone-Banks2023.
Safety of Varenicline
Varenicline is associated with a higher likelihood of serious adverse events compared to placebo, although the evidence is mixed regarding specific risks such as cardiac or neuropsychiatric events . Further research is needed to fully understand the safety profile of varenicline.
Cytisine
Efficacy of Cytisine
Cytisine, another nicotine receptor partial agonist, has shown positive results in aiding smoking cessation. It is particularly noted for its affordability and effectiveness, with a risk ratio (RR) of 3.98 compared to placebo .
Safety of Cytisine
Cytisine has not been associated with significant adverse events, making it a promising option for smoking cessation, especially in regions where it is licensed Cahill2013Livingstone-Banks2023.
Nortriptyline
Efficacy of Nortriptyline
Nortriptyline, an antidepressant, has also been found to aid smoking cessation. It increases the chances of quitting compared to placebo, with a risk ratio (RR) of 2.03 Cahill2013Howes2020. However, it is less effective than bupropion and varenicline .
Safety of Nortriptyline
Nortriptyline is associated with adverse events, and its combination with NRT does not enhance the effect compared to NRT alone . Therefore, its use should be carefully considered.
Combined Pharmacotherapy and Behavioral Interventions
Combining pharmacotherapy with behavioral support significantly increases the chances of quitting smoking compared to minimal intervention or usual care. This combination approach is recommended for its higher efficacy, with a risk ratio (RR) of 1.83 .
Conclusion
In summary, several pharmacological interventions are available to aid smoking cessation, each with varying degrees of efficacy and safety profiles. NRT, bupropion, varenicline, and cytisine have all been shown to improve the chances of quitting smoking. Combining these medications with behavioral support further enhances their effectiveness. While all these treatments are generally safe, monitoring for adverse events is crucial, particularly with bupropion and varenicline. Further research is warranted to explore the long-term safety and efficacy of these medications, especially newer options like cytisine.
Sources and full results
Most relevant research papers on this topic
Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
Nicotine replacement therapy, bupropion, and varenicline effectively help smokers achieve long-term abstinence, with varenicline showing the highest odds of quitting compared to placebo.
Combined pharmacotherapy and behavioural interventions for smoking cessation.
Combining behavioral support and medication is effective in aiding smoking cessation, but the effects vary depending on the treatment setting, intervention, population treated, or treatment take-up.
Varenicline for smoking reduction in smokers not yet ready to quit: A double-blind, proof-of-concept randomized clinical trial.
Varenicline can effectively reduce cigarettes per day in smokers not yet ready to quit, increasing their self-efficacy for later quitting.
Beyond "Safe and Effective": The urgent need for high-impact smoking cessation medications.
High-impact smoking cessation medications with behavioral support are urgently needed to effectively increase cessation and reduce population smoking prevalence.
Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences.
Naltrexone may improve smoking cessation rates and reduce weight gain, particularly in female smokers, with potential benefits for both men and women.
DOI